middle.news
Noxopharm Advances HERACLES Trial with Safe Low-Dose SOF-SKN Completion
9:49am on Monday 28th of July, 2025 AEST
•
Biotechnology
Read Story
Noxopharm Advances HERACLES Trial with Safe Low-Dose SOF-SKN Completion
9:49am on Monday 28th of July, 2025 AEST
Key Points
First low-dose cohort of SOF-SKN™ completed with positive safety results
Safety steering committee approves progression to higher dose cohort
HERACLES trial focuses on safety, tolerability, and dose escalation
SOF-SKN™ targets autoimmune diseases including cutaneous lupus erythematosus
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NOX
OPEN ARTICLE